These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 1621098)

  • 41. Substrate specificity of reduced and oxidized forms of human aldose reductase.
    Vander Jagt DL; Hunsaker LA
    Adv Exp Med Biol; 1993; 328():279-88. PubMed ID: 8493905
    [No Abstract]   [Full Text] [Related]  

  • 42. Structure of rat aldose reductase-like protein AKR1B14 holoenzyme: Probing the role of His269 in coenzyme binding by site-directed mutagenesis.
    Sundaram K; Dhagat U; Endo S; Chung R; Matsunaga T; Hara A; El-Kabbani O
    Bioorg Med Chem Lett; 2011 Jan; 21(2):801-4. PubMed ID: 21168333
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The structure of apo and holo forms of xylose reductase, a dimeric aldo-keto reductase from Candida tenuis.
    Kavanagh KL; Klimacek M; Nidetzky B; Wilson DK
    Biochemistry; 2002 Jul; 41(28):8785-95. PubMed ID: 12102621
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Crystal structure of Escherichia coli thioredoxin reductase refined at 2 A resolution. Implications for a large conformational change during catalysis.
    Waksman G; Krishna TS; Williams CH; Kuriyan J
    J Mol Biol; 1994 Feb; 236(3):800-16. PubMed ID: 8114095
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Aldehyde reductase: the role of C-terminal residues in defining substrate and cofactor specificities.
    Rees-Milton KJ; Jia Z; Green NC; Bhatia M; El-Kabbani O; Flynn TG
    Arch Biochem Biophys; 1998 Jul; 355(2):137-44. PubMed ID: 9675019
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Active site modification of aldose reductase by nitric oxide donors.
    Chandra A; Srivastava S; Petrash JM; Bhatnagar A; Srivastava SK
    Biochim Biophys Acta; 1997 Sep; 1341(2):217-22. PubMed ID: 9357961
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ultrahigh resolution drug design. II. Atomic resolution structures of human aldose reductase holoenzyme complexed with Fidarestat and Minalrestat: implications for the binding of cyclic imide inhibitors.
    El-Kabbani O; Darmanin C; Schneider TR; Hazemann I; Ruiz F; Oka M; Joachimiak A; Schulze-Briese C; Tomizaki T; Mitschler A; Podjarny A
    Proteins; 2004 Jun; 55(4):805-13. PubMed ID: 15146479
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Atomic structure of ferredoxin-NADP+ reductase: prototype for a structurally novel flavoenzyme family.
    Karplus PA; Daniels MJ; Herriott JR
    Science; 1991 Jan; 251(4989):60-6. PubMed ID: 1986412
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Human aldose reductase: pK of tyrosine 48 reveals the preferred ionization state for catalysis and inhibition.
    Grimshaw CE; Bohren KM; Lai CJ; Gabbay KH
    Biochemistry; 1995 Nov; 34(44):14374-84. PubMed ID: 7578041
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Structure of aldose reductase from Giardia lamblia.
    Ferrell M; Abendroth J; Zhang Y; Sankaran B; Edwards TE; Staker BL; Van Voorhis WC; Stewart LJ; Myler PJ
    Acta Crystallogr Sect F Struct Biol Cryst Commun; 2011 Sep; 67(Pt 9):1113-7. PubMed ID: 21904059
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Stereospecific interaction of a novel spirosuccinimide type aldose reductase inhibitor, AS-3201, with aldose reductase.
    Kurono M; Fujiwara I; Yoshida K
    Biochemistry; 2001 Jul; 40(28):8216-26. PubMed ID: 11444967
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The C-terminal loop of aldehyde reductase determines the substrate and inhibitor specificity.
    Barski OA; Gabbay KH; Bohren KM
    Biochemistry; 1996 Nov; 35(45):14276-80. PubMed ID: 8916913
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Diabetic cataracts and flavonoids.
    Varma SD; Mizuno A; Kinoshita JH
    Science; 1977 Jan; 195(4274):205-6. PubMed ID: 401544
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The crystal structure of NADPH:ferredoxin reductase from Azotobacter vinelandii.
    Sridhar Prasad G; Kresge N; Muhlberg AB; Shaw A; Jung YS; Burgess BK; Stout CD
    Protein Sci; 1998 Dec; 7(12):2541-9. PubMed ID: 9865948
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Alkaloids as aldose reductase inhibitors, with special reference to berberine.
    Gupta S; Singh N; Jaggi AS
    J Altern Complement Med; 2014 Mar; 20(3):195-205. PubMed ID: 24236461
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A novel NAD(P)H-dependent carbonyl reductase specifically expressed in the thyroidectomized chicken fatty liver: catalytic properties and crystal structure.
    Fukuda Y; Sone T; Sakuraba H; Araki T; Ohshima T; Shibata T; Yoneda K
    FEBS J; 2015 Oct; 282(20):3918-28. PubMed ID: 26206323
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparative anatomy of the aldo-keto reductase superfamily.
    Jez JM; Bennett MJ; Schlegel BP; Lewis M; Penning TM
    Biochem J; 1997 Sep; 326 ( Pt 3)(Pt 3):625-36. PubMed ID: 9307009
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Research progress in aldose reductase].
    Gu J; Yan J; Wu W; Huang Q; Ouyang D
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Apr; 35(4):395-400. PubMed ID: 20448367
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Probing the substrate binding site of Candida tenuis xylose reductase (AKR2B5) with site-directed mutagenesis.
    Kratzer R; Leitgeb S; Wilson DK; Nidetzky B
    Biochem J; 2006 Jan; 393(Pt 1):51-8. PubMed ID: 16336198
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of aldose reductase inhibition and docking studies of some secondary metabolites, isolated from Origanum vulgare L. ssp. hirtum.
    Koukoulitsa C; Zika C; Geromichalos GD; Demopoulos VJ; Skaltsa H
    Bioorg Med Chem; 2006 Mar; 14(5):1653-9. PubMed ID: 16249088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.